UNIGE document Scientific Article
previous document  unige:99092  next document
add to browser collection
Title

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Authors
Maury, Sébastien
Chevret, Sylvie
Thomas, Xavier
Heim, Dominik
Leguay, Thibaut
Huguet, Françoise
Chevallier, Patrice
Hunault, Mathilde
show hidden authors show all authors [1 - 22]
Published in New England Journal of Medicine. 2016, vol. 375, no. 11, p. 1044-1053
Abstract Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial.
Keywords AdolescentAdultAntigens, CD20/analysisAntineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic useDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/immunologyPrognosisRemission InductionRituximab/administration & dosage/adverse effectsYoung Adult
Identifiers
PMID: 27626518
Full text
Article (Published version) (294 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)
Citation
(ISO format)
MAURY, Sébastien et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. In: New England Journal of Medicine, 2016, vol. 375, n° 11, p. 1044-1053. https://archive-ouverte.unige.ch/unige:99092

140 hits

0 download

Update

Deposited on : 2017-11-16

Export document
Format :
Citation style :